Glucose-lowering therapy does not slow progression in young people with type 2 diabetes
Despite previous suggestions that early intervention with insulin therapy may benefit long-term outcomes for people with prediabetes, new research indicates that this is not the case in young people.
Treatment with insulin glargine does not maintain or improve pancreatic beta-cell function in young people recently diagnosed with impaired glucose tolerance or type 2 diabetes mellitus (T2DM) taking metformin, a study has shown.
The research included 91 overweight and obese people aged 10–19 years diagnosed with impaired glucose tolerance or T2DM within the previous 6 months, randomly assigned to either 3 months’ treatment with insulin glargine (target glucose 4.4–5.0 mmol/L) followed by 9 months of metformin or 12 months of metformin alone.
The team found no difference in beta-cell function, HbA1c, fasting blood glucose, body mass index or glucose tolerance between groups at 12 and 15 months. In both groups, beta-cell function had declined significantly from baseline at months 12 and 15.
Previous research has indicated that early intervention with insulin therapy might benefit long-term outcomes in people with prediabetes. The authors of the current study said their findings indicate that this is not the case in young people.
“There is an urgent and growing need for more research to find options to adequately slow or prevent progression of T2DM in youth,” said principal investigator Kristen Nadeau from the University of Colorado.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205332
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now